The 9th Annual IBDHorizons Pacific Northwest Symposium Scientific Program Committee invites you to submit abstracts reporting new research or developing information in the field of Inflammatory Bowel Disease (IBD).
We welcome abstracts presenting studies, case reports, systematic reviews and quality improvement projects. The Scientific Program Committee will select abstracts on the basis of their medical significance, the quality of the data, methodology, and adherence to specific format requirements described below. The accepted abstracts will be offered the opportunity to be presented as posters, and select abstracts will be invited for oral presentation.
9th Annual IBDHorizons Pacific Northwest Symposium
The two best abstracts will be selected by the Scientific Program Committee for the 9th Annual IBDHorizons Pacific Northwest Symposium and awarded a grant of $1,000 and $500 for 1st and 2nd place, respectively.
1st place: $1,000
2nd place: $500
The abstract author will be invited for an oral podium presentation at the conference in Seattle, Washington.
All accepted abstracts are invited for poster presentation during the symposium.
Resubmit an abstract you have recently presented and have an opportunity to receive additional feedback before working on a manuscript.
The titles of abstracts should not exceed 15 words. The body text should not exceed 350 words. Embedded images (tables, figures, etc.) will be counted as 30 words.
Each abstract must include the following:
Title: The title should appear in boldface at the top. It should be concise (<150 characters, not including spaces)
Authors’ names
Background: Describe the hypothesis of the abstract
Methods: Detail the experimental methods and processes employed in the study.
Results: Include the findings of the study in a concise manner.
Conclusions: This section describes logically sound conclusions and reliable inferences from the results.
December 6, 2023 – Abstract Submission Opens
February 17, 2024 – Last day to submit
February 27, 2024 – Decisions of abstract acceptance emailed
Clarity: Keep all elements of your poster (incl. pictures, tables, graphics, etc.) simple.
Language: All posters must be in English.
Visibility: Visitors have to be able to read the poster from a distance of up to 4 feet.
Your poster should be structured to include: background, methods, results, conclusion.
Your poster should not require extensive clarification, but be self-explanatory.
Dimensions
Maximum height: 50 inches
Maximum width: 35 inches
Posters will be fixed to boards using push pins supplied on-site.
The posters should be up for the entire session and presenters are encouraged to be at their posters during the full poster session time (see program agenda for poster viewing times).
Please create a one page file for your abstract in either .doc, .docx, .pdf, or .rtf format
The healthcare system is constantly evolving—but what’s driving the biggest shifts?
From AI and telehealth to demographic changes and policy reform, many forces are reshaping how we deliver care.
In your opinion, which ONE is the most critical source of change in healthcare…
Such a treat having you with us @IBD_Afzali! Thank you for the thoughtful insights and wisdom you shared on IBD. @AmCollegeGastro @swathipaleti
Congratulations Anita. I’m sure everyone learned a lot!
Dr Scott Lee @DrScottDLee educating us about combination advanced therapy CAT in #IBD #SIBD_24
Dr Iles-Shih @SwedishGastro teaching us how to alleviate patient and provider concerns about using biosimilars in #IBD #SIBD_2024
On #WorldIBDDay, #IBDHasNoBorders
Across the globe we are:
Educating clinicians & our patients with #IBD
Researching treatments
Raising awareness
Building #IBDCenters
Together, we fight IBD.
To our patients: We’re 
with you
#WorldIBDay2024 #IBDAwareness
That's a wrap 
City of Roses 
@IBDHorizons X @OregonClinic Symposium. Thank you Dr Don Lum, all Faculty Speakers, Industry Partners and our fantastic, engaged Attendees. See you in 2025, PDX! #IBDHorizons24 Join us for an upcoming Symposium 
http://ibdhorizons.org
Higher ustekinumab concentrations associated with less inflammation on cross sectional imaging on #mri in #crohns disease
@DrRosenIBD @UmaMahadevanIBD @ryanungaro
#SpeakerSpotlight 
#SpeakerSpotlight 
Congrats grant recipients! Notification emails
;
;
;
;
;